Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: February 27, 2026, 1:52 pm
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: | NSE:

Beta Drugs Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: February 27, 2026, 1:52 pm

Market Cap 1,047 Cr.
Current Price 1,033
Intrinsic Value₹1,448.93
High / Low 2,000/990
Stock P/E24.3
Book Value 219
Dividend Yield0.00 %
ROCE27.0 %
ROE25.9 %
Face Value 10.0
PEG Ratio0.83

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Beta Drugs Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lactose (India) Ltd 121 Cr. 96.0 137/84.325.0 49.60.00 %12.9 %9.69 % 10.0
MPS Pharmaa Ltd 3.15 Cr. 1.65 3.69/1.60 0.330.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 3,313 Cr. 304 479/20869.4 24.30.21 %27.3 %21.7 % 1.00
Gujarat Terce Laboratories Ltd 31.2 Cr. 40.0 76.9/37.2 10.10.00 %41.4 %14.6 % 10.0
Gujarat Inject (Kerala) Ltd 94.0 Cr. 64.2 64.7/17.0376 6.930.00 %13.5 %11.0 % 10.0
Industry Average20,673.07 Cr1,097.3656.27201.210.37%16.35%15.16%6.10

All Competitor Stocks of Beta Drugs Ltd

Quarterly Result

MetricSep 2019Mar 2020Sep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025
Sales 474451658896112115141154180182204
Expenses 3736415168738688108127141146163
Operating Profit 981114202327263327393641
OPM % 20%19%21%22%23%24%24%23%23%18%22%20%20%
Other Income 0000000011206
Interest 1211111111257
Depreciation 2234345654678
Profit before tax 7579161821202722332432
Tax % 27%14%21%30%28%27%25%25%25%25%25%26%25%
Net Profit 5457121316152017241824
EPS in Rs 5.074.255.136.4811.6312.9515.6714.7319.6716.4024.2017.8123.70

Last Updated: January 2, 2026, 7:02 am

Below is a detailed analysis of the quarterly data for Beta Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Sales, as of Sep 2025, the value is 204.00 Cr.. The value appears strong and on an upward trend. It has increased from 182.00 Cr. (Mar 2025) to 204.00 Cr., marking an increase of 22.00 Cr..
  • For Expenses, as of Sep 2025, the value is 163.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 146.00 Cr. (Mar 2025) to 163.00 Cr., marking an increase of 17.00 Cr..
  • For Operating Profit, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 5.00 Cr..
  • For OPM %, as of Sep 2025, the value is 20.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 20.00%.
  • For Other Income, as of Sep 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 6.00 Cr..
  • For Interest, as of Sep 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 2.00 Cr..
  • For Depreciation, as of Sep 2025, the value is 8.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 1.00 Cr..
  • For Profit before tax, as of Sep 2025, the value is 32.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Mar 2025) to 32.00 Cr., marking an increase of 8.00 Cr..
  • For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to 25.00%, marking a decrease of 1.00%.
  • For Net Profit, as of Sep 2025, the value is 24.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2025) to 24.00 Cr., marking an increase of 6.00 Cr..
  • For EPS in Rs, as of Sep 2025, the value is 23.70. The value appears strong and on an upward trend. It has increased from 17.81 (Mar 2025) to 23.70, marking an increase of 5.89.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 23, 2026, 2:16 pm

MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Sales 516691116184227296362
Expenses 41547391141174236288
Operating Profit 912182543536075
OPM % 19%18%20%21%23%23%20%21%
Other Income 00001112
Interest 11322237
Depreciation 23477101013
Profit before tax 78121634414957
Tax % 1%-2%21%27%28%25%25%26%
Net Profit 7891225313642
EPS in Rs 7.438.849.3311.6024.5830.4236.0842.02
Dividend Payout % 0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)14.29%12.50%33.33%108.33%24.00%16.13%16.67%
Change in YoY Net Profit Growth (%)0.00%-1.79%20.83%75.00%-84.33%-7.87%0.54%

Beta Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:32%
3 Years:25%
TTM:23%
Compounded Profit Growth
10 Years:%
5 Years:37%
3 Years:23%
TTM:26%
Stock Price CAGR
10 Years:%
5 Years:87%
3 Years:36%
1 Year:12%
Return on Equity
10 Years:%
5 Years:26%
3 Years:27%
Last Year:26%

Last Updated: September 5, 2025, 12:45 am

Balance Sheet

Last Updated: January 7, 2026, 3:27 pm

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 9910101010101010
Reserves 2432485983113148187211
Borrowings 8202317212015138146
Other Liabilities 9222831455582101121
Total Liabilities 5083107118158198254436488
Fixed Assets 1318444055636589112
CWIP 1150300000
Investments 000111000
Other Assets 35506374102135190347376
Total Assets 5083107118158198254436488

Below is a detailed analysis of the balance sheet data for Beta Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
  • For Reserves, as of Sep 2025, the value is 211.00 Cr.. The value appears strong and on an upward trend. It has increased from 187.00 Cr. (Mar 2025) to 211.00 Cr., marking an increase of 24.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 146.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 138.00 Cr. (Mar 2025) to 146.00 Cr., marking an increase of 8.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 121.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 101.00 Cr. (Mar 2025) to 121.00 Cr., marking an increase of 20.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 488.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 436.00 Cr. (Mar 2025) to 488.00 Cr., marking an increase of 52.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 112.00 Cr.. The value appears strong and on an upward trend. It has increased from 89.00 Cr. (Mar 2025) to 112.00 Cr., marking an increase of 23.00 Cr..
  • For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
  • For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 376.00 Cr.. The value appears strong and on an upward trend. It has increased from 347.00 Cr. (Mar 2025) to 376.00 Cr., marking an increase of 29.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 488.00 Cr.. The value appears strong and on an upward trend. It has increased from 436.00 Cr. (Mar 2025) to 488.00 Cr., marking an increase of 52.00 Cr..

Notably, the Reserves (211.00 Cr.) exceed the Borrowings (146.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 17081930233136
Cash from Investing Activity + -11-21-15-6-22-19-14-36
Cash from Financing Activity + 5129-8-1-2-7118
Net Cash Flow 12-925729118

Free Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow1.00-8.00-5.008.0022.0033.0045.00-63.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 1041391281069010198103
Inventory Days 3710410210087106122127
Days Payable 81143119127123139145152
Cash Conversion Cycle 601001117953687579
Working Capital Days 5040567661738082
ROCE %18%21%22%36%34%33%27%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 66.73%66.73%66.73%66.73%66.73%66.73%66.73%66.73%66.73%66.73%66.73%64.90%
FIIs 0.29%0.29%0.32%0.32%0.32%0.90%1.16%1.15%0.90%0.90%0.90%1.14%
DIIs 0.04%0.04%0.02%0.02%0.06%0.12%0.16%0.17%0.17%0.26%0.29%1.90%
Public 32.94%32.93%32.93%32.92%32.87%32.25%31.95%31.95%32.20%32.11%32.07%32.07%
No. of Shareholders 1,4241,4511,7221,9282,1162,3232,5672,8823,0543,1393,1843,694

Shareholding Pattern Chart

No. of Shareholders

Beta Drugs Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 42.0237.9031.9525.8212.20
Diluted EPS (Rs.) 42.0237.9031.9525.8212.20
Cash EPS (Rs.) 54.4248.0842.7833.3719.34
Book Value[Excl.RevalReserv]/Share (Rs.) 195.25163.43127.8296.0571.37
Book Value[Incl.RevalReserv]/Share (Rs.) 195.25163.43127.8296.0571.37
Revenue From Operations / Share (Rs.) 358.96307.59236.24191.22120.79
PBDIT / Share (Rs.) 80.2863.8256.0545.2026.26
PBIT / Share (Rs.) 67.8953.6545.2237.6519.11
PBT / Share (Rs.) 56.4450.7142.7035.6816.59
Net Profit / Share (Rs.) 42.0237.9031.9525.8212.20
NP After MI And SOA / Share (Rs.) 42.0237.9031.9525.8212.20
PBDIT Margin (%) 22.3620.7423.7223.6321.73
PBIT Margin (%) 18.9117.4419.1419.6915.81
PBT Margin (%) 15.7216.4818.0718.6513.73
Net Profit Margin (%) 11.7012.3213.5213.5010.09
NP After MI And SOA Margin (%) 11.7012.3213.5213.5010.09
Return on Networth / Equity (%) 21.5223.1924.9926.8817.08
Return on Capital Employeed (%) 20.5430.4332.1033.2422.09
Return On Assets (%) 9.7214.3315.4815.729.97
Long Term Debt / Equity (X) 0.640.030.050.120.16
Total Debt / Equity (X) 0.670.060.130.170.21
Asset Turnover Ratio (%) 1.051.311.271.090.82
Current Ratio (X) 3.222.102.031.981.99
Quick Ratio (X) 2.641.511.541.521.53
Inventory Turnover Ratio (X) 6.614.174.165.704.47
Interest Coverage Ratio (X) 11.6021.7622.3122.8810.43
Interest Coverage Ratio (Post Tax) (X) 7.7213.9213.7214.075.85
Enterprise Value (Cr.) 1909.201168.47599.62542.92119.61
EV / Net Operating Revenue (X) 5.273.952.642.951.03
EV / EBITDA (X) 23.5619.0411.1312.494.74
MarketCap / Net Operating Revenue (X) 5.314.012.652.960.99
Price / BV (X) 9.767.554.905.891.68
Price / Net Operating Revenue (X) 5.314.012.652.960.99
EarningsYield 0.020.030.050.040.10

After reviewing the key financial ratios for Beta Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
  • For Cash EPS (Rs.), as of Mar 25, the value is 54.42. This value is within the healthy range. It has increased from 48.08 (Mar 24) to 54.42, marking an increase of 6.34.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 195.25. It has increased from 163.43 (Mar 24) to 195.25, marking an increase of 31.82.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 195.25. It has increased from 163.43 (Mar 24) to 195.25, marking an increase of 31.82.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 358.96. It has increased from 307.59 (Mar 24) to 358.96, marking an increase of 51.37.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 80.28. This value is within the healthy range. It has increased from 63.82 (Mar 24) to 80.28, marking an increase of 16.46.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 67.89. This value is within the healthy range. It has increased from 53.65 (Mar 24) to 67.89, marking an increase of 14.24.
  • For PBT / Share (Rs.), as of Mar 25, the value is 56.44. This value is within the healthy range. It has increased from 50.71 (Mar 24) to 56.44, marking an increase of 5.73.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
  • For PBDIT Margin (%), as of Mar 25, the value is 22.36. This value is within the healthy range. It has increased from 20.74 (Mar 24) to 22.36, marking an increase of 1.62.
  • For PBIT Margin (%), as of Mar 25, the value is 18.91. This value is within the healthy range. It has increased from 17.44 (Mar 24) to 18.91, marking an increase of 1.47.
  • For PBT Margin (%), as of Mar 25, the value is 15.72. This value is within the healthy range. It has decreased from 16.48 (Mar 24) to 15.72, marking a decrease of 0.76.
  • For Net Profit Margin (%), as of Mar 25, the value is 11.70. This value exceeds the healthy maximum of 10. It has decreased from 12.32 (Mar 24) to 11.70, marking a decrease of 0.62.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 11.70. This value is within the healthy range. It has decreased from 12.32 (Mar 24) to 11.70, marking a decrease of 0.62.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 21.52. This value is within the healthy range. It has decreased from 23.19 (Mar 24) to 21.52, marking a decrease of 1.67.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 20.54. This value is within the healthy range. It has decreased from 30.43 (Mar 24) to 20.54, marking a decrease of 9.89.
  • For Return On Assets (%), as of Mar 25, the value is 9.72. This value is within the healthy range. It has decreased from 14.33 (Mar 24) to 9.72, marking a decrease of 4.61.
  • For Long Term Debt / Equity (X), as of Mar 25, the value is 0.64. This value is within the healthy range. It has increased from 0.03 (Mar 24) to 0.64, marking an increase of 0.61.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.67. This value is within the healthy range. It has increased from 0.06 (Mar 24) to 0.67, marking an increase of 0.61.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 1.05. It has decreased from 1.31 (Mar 24) to 1.05, marking a decrease of 0.26.
  • For Current Ratio (X), as of Mar 25, the value is 3.22. This value exceeds the healthy maximum of 3. It has increased from 2.10 (Mar 24) to 3.22, marking an increase of 1.12.
  • For Quick Ratio (X), as of Mar 25, the value is 2.64. This value exceeds the healthy maximum of 2. It has increased from 1.51 (Mar 24) to 2.64, marking an increase of 1.13.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.61. This value is within the healthy range. It has increased from 4.17 (Mar 24) to 6.61, marking an increase of 2.44.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 11.60. This value is within the healthy range. It has decreased from 21.76 (Mar 24) to 11.60, marking a decrease of 10.16.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.72. This value is within the healthy range. It has decreased from 13.92 (Mar 24) to 7.72, marking a decrease of 6.20.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 1,909.20. It has increased from 1,168.47 (Mar 24) to 1,909.20, marking an increase of 740.73.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.27. This value exceeds the healthy maximum of 3. It has increased from 3.95 (Mar 24) to 5.27, marking an increase of 1.32.
  • For EV / EBITDA (X), as of Mar 25, the value is 23.56. This value exceeds the healthy maximum of 15. It has increased from 19.04 (Mar 24) to 23.56, marking an increase of 4.52.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.31. This value exceeds the healthy maximum of 3. It has increased from 4.01 (Mar 24) to 5.31, marking an increase of 1.30.
  • For Price / BV (X), as of Mar 25, the value is 9.76. This value exceeds the healthy maximum of 3. It has increased from 7.55 (Mar 24) to 9.76, marking an increase of 2.21.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.31. This value exceeds the healthy maximum of 3. It has increased from 4.01 (Mar 24) to 5.31, marking an increase of 1.30.
  • For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Beta Drugs Ltd as of February 27, 2026 is: ₹1,124.71

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 27, 2026, Beta Drugs Ltd is Undervalued by 8.88% compared to the current share price ₹1,033.00

Intrinsic Value of Beta Drugs Ltd as of February 27, 2026 is: ₹1,454.92

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 27, 2026, Beta Drugs Ltd is Undervalued by 40.84% compared to the current share price ₹1,033.00

Last 5 Year EPS CAGR: 29.36%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 23.88%, which is a positive sign.
  2. The company has higher reserves (100.56 cr) compared to borrowings (45.33 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (174.13 cr) and profit (28.00 cr) over the years.
  1. The stock has a high average Working Capital Days of 64.75, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 78.13, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Beta Drugs Ltd:
    1. Net Profit Margin: 11.7%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 20.54% (Industry Average ROCE: 16.35%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 21.52% (Industry Average ROE: 15.16%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 7.72
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 2.64
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 24.3 (Industry average Stock P/E: 56.27)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.67
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Beta Drugs Ltd. is a Public Limited Listed company incorporated on 21/09/2015 and has its registered office in the State of Himachal Pradesh, India. Company's Corporate Identification Number(CIN) is L24230HP2005PLC028969 and registration number is 028969. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 220.20 Cr. and Equity Capital is Rs. 10.09 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsVillage Nandpur, Baddi Himachal Pradesh 174101Contact not found
Management
NamePosition Held
Mr. Rahul BatraChairperson & Managing Director
Mr. Varun BatraJoint Managing Director
Mr. Ashutosh ShuklaWhole Time Director
Mr. Balwant SinghWhole Time Director
Mr. Ajay MahipalDirector
Mr. Manmohan KhannaIndependent Director
Mr. Rohit PartiIndependent Director
Mrs. Monica JainIndependent Director
Mr. Sanjay SehgalIndependent Director
Mr. Lalit Kumar WattsIndependent Director

FAQ

What is the intrinsic value of Beta Drugs Ltd?

Beta Drugs Ltd's intrinsic value (as of 27 February 2026) is ₹1454.92 which is 40.84% higher the current market price of ₹1,033.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,047 Cr. market cap, FY2025-2026 high/low of ₹2,000/990, reserves of ₹211 Cr, and liabilities of ₹488 Cr.

What is the Market Cap of Beta Drugs Ltd?

The Market Cap of Beta Drugs Ltd is 1,047 Cr..

What is the current Stock Price of Beta Drugs Ltd as on 27 February 2026?

The current stock price of Beta Drugs Ltd as on 27 February 2026 is ₹1,033.

What is the High / Low of Beta Drugs Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Beta Drugs Ltd stocks is ₹2,000/990.

What is the Stock P/E of Beta Drugs Ltd?

The Stock P/E of Beta Drugs Ltd is 24.3.

What is the Book Value of Beta Drugs Ltd?

The Book Value of Beta Drugs Ltd is 219.

What is the Dividend Yield of Beta Drugs Ltd?

The Dividend Yield of Beta Drugs Ltd is 0.00 %.

What is the ROCE of Beta Drugs Ltd?

The ROCE of Beta Drugs Ltd is 27.0 %.

What is the ROE of Beta Drugs Ltd?

The ROE of Beta Drugs Ltd is 25.9 %.

What is the Face Value of Beta Drugs Ltd?

The Face Value of Beta Drugs Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Beta Drugs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports